Skip to main content

Table 1 Baseline Characteristics of the Study Subjects:

From: Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD

  COPD non-smokers (N = 13) COPD smokers (N = 8) Control non-smokers (N = 12) Control smokers (N = 9)
Mean age (95% CI) 72.8 (69.4-76.3) 62.3 (58.7 - 65.8) 66.7 (62.4-70.9) 56.4 (52.7-60.1)
Female Gender 7 (54%) 5 (63%) 7 (58%) 6 (67%)
Mean BMI (95% CI) 28.3 (25.4-31.2) 25.5 (20.9-30.2) 25.8 (23.9-27.7) 26.0 (24.5-27.6)
Pack Years (95% CI) 44.5 (33.7-55.2) 53.8 (44.5-63.0) 0 29.3 (22.0-36.7)
Post-bronchodilator FEV1% predicted 46 (39 - 53) 44 (33 - 54) 101 (92-111) 102 (93-111)
GOLD Stage II 6 (46%) 3 (38%) 0 0
GOLD Stage III 6 (46%) 3 (38%) 0 0
GOLD Stage IV 1 (8%) 2 (25%) 0 0
History of Chronic Bronchitis 7 (54%) 8 (100%) 0 (0%) 3 (33%)
Total lung capacity % predicted 122 (108 - 136) 117 (106-127) 103 (96-110) 106 (99-114)
Residual volume % predicted 172 (132 - 211) 176 (150-201) 93 (81-104) 94 (81-108)
Diffusion capacity (DLCO % predicted 64 (56 - 73) 64 (50-78) 86 (82-90) 78 (71-84)
Baseline Dyspnea Index Score (95% CI) 6.0 (4.7 - 7.4) 6.5 (4.7 - 8.2) 11.6 (11.2-11.9) 10.9 (10.1-11.6)
Use of inhaled corticosteroids 10 (77%) 7 (88%) 0 0
\